These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39153094)

  • 1. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide.
    Tashiro Y; Akamatsu S; Ueno K; Kamoto T; Terada N; Hida T; Kurahashi R; Kamba T; Saito A; Lee T; Morita S; Kobayashi T
    Int J Clin Oncol; 2024 Oct; 29(10):1564-1573. PubMed ID: 39153094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
    Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N
    Eur Urol Oncol; 2024 Oct; 7(5):1097-1104. PubMed ID: 38523017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
    Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
    Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
    Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
    Yokomizo Y; Kawahara T; Miyoshi Y; Otani M; Yamanaka S; Teranishi J; Noguchi K; Yao M; Uemura H
    Biomed Res Int; 2016; 2016():4083183. PubMed ID: 27493956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
    JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
    Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
    Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
    Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute.
    Miyazawa Y; Sekine Y; Arai S; Oka D; Nakayama H; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
    In Vivo; 2021; 35(1):373-384. PubMed ID: 33402486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Watanabe H; Nakane K; Takahara K; Naiki T; Yasui T; Shiroki R; Koie T; Miyake H
    Int J Urol; 2024 Sep; 31(9):986-993. PubMed ID: 38764245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.